Bristol Myers Squibb (BMY) Receivables (2009 - 2026)

Bristol Myers Squibb has disclosed Receivables across 18 years of filings, most recently posting $9.5 billion for Q1 2026.

• In Q1 2026, Receivables fell 24.1% year-over-year to $9.5 billion; the TTM figure through Mar 2026 stood at $9.5 billion (down 24.1% YoY), while the FY2025 annual figure was $13.2 billion, up 18.89% from the prior year.
• Receivables eased to $9.5 billion in Q1 2026, from $13.2 billion in the prior quarter.
• Over the last five years, Receivables for BMY reached as high as $13.2 billion in Q4 2025 and fell as low as $8.9 billion in Q1 2022.
• The 5-year median for Receivables is $11.1 billion (2024), against an average of $11.0 billion.
• Annual changes were most pronounced in 2025 — Receivables increased 18.89% — and 2026, when it dropped 24.1%.
• A 5-year view of Receivables shows it stood at $10.4 billion in 2022, then advanced by 9.11% to $11.3 billion in 2023, then retreated by 1.81% to $11.1 billion in 2024, then advanced by 18.89% to $13.2 billion in 2025, then decreased by 28.09% to $9.5 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $9.5 billion, $13.2 billion, and $11.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.